Published in Methods Enzymol on January 01, 2005
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J Am Chem Soc (2008) 2.56
Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther (2009) 2.39
Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine (2010) 1.19
Multiple lipid compartments slow vesicle contents release in lipases and serum. ACS Nano (2007) 1.16
Electron tomography in nanoparticle imaging and analysis. Nanomedicine (Lond) (2008) 1.00
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A (2014) 1.00
From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug Chem (2013) 0.95
Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) (2010) 0.90
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89
Microfluidic methods for production of liposomes. Methods Enzymol (2009) 0.88
Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int J Pharm (2009) 0.87
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs (2009) 0.85
Internalization of paramagnetic phosphatidylserine-containing liposomes by macrophages. J Nanobiotechnology (2012) 0.84
Therapeutic surfactant-stripped frozen micelles. Nat Commun (2016) 0.82
Near-infrared light-sensitive liposomes for the enhanced photothermal tumor treatment by the combination with chemotherapy. Pharm Res (2014) 0.82
Prevention of orthopedic device-associated osteomyelitis using oxacillin-containing biomineral-binding liposomes. Pharm Res (2012) 0.82
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. Int J Nanomedicine (2012) 0.81
Fiber-optic triggered release of liposome in vivo: implication of personalized chemotherapy. Int J Nanomedicine (2015) 0.79
Gold nanoparticles electroporation enhanced polyplex delivery to mammalian cells. Electrophoresis (2014) 0.79
Microfluidic remote loading for rapid single-step liposomal drug preparation. Lab Chip (2014) 0.78
Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. J Control Release (2011) 0.78
Ultrasound-enhanced microfluidic synthesis of liposomes. Anticancer Res (2010) 0.77
Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development. PLoS One (2016) 0.77
Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine (Lond) (2015) 0.76
Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence. J Pharm Biomed Anal (2009) 0.76
Synthetic lethality in lung cancer and translation to clinical therapies. Mol Cancer (2016) 0.75
Particle-based technologies for osteoarthritis detection and therapy. Drug Deliv Transl Res (2016) 0.75
Antibody-based therapeutics for the treatment of human B cell malignancies. Curr Allergy Asthma Rep (2013) 0.75
Hydrophobic Drug-Loaded PEGylated Magnetic Liposomes for Drug-Controlled Release. Nanoscale Res Lett (2017) 0.75
Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. Int J Nanomedicine (2016) 0.75
The Use of Anthracyclines for Therapy of CNS Tumors. Anticancer Agents Med Chem (2015) 0.75
Engineering Remotely Triggered Liposomes to Target Triple Negative Breast Cancer. Oncomedicine (2017) 0.75
A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats. Iran J Pharm Res (2015) 0.75
Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS One (2017) 0.75
Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells. Cell Mol Bioeng (2017) 0.75
Contribution of Kupffer cells to liposome accumulation in the liver. Colloids Surf B Biointerfaces (2017) 0.75
Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. Pharm Res (2017) 0.75
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40
Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res (2008) 2.20
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst (2007) 2.03
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl (2012) 1.87
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res (2003) 1.39
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther (2004) 1.39
A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res (2011) 1.33
Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res (2006) 1.31
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol (2011) 1.29
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J Med Chem (2008) 1.28
Liposomal nanomedicines. Expert Opin Drug Deliv (2008) 1.26
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther (2011) 1.23
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med (2004) 1.20
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene (2005) 1.14
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir (2012) 1.13
Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release (2005) 1.12
Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta (2003) 1.11
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther (2013) 1.11
Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med (2006) 1.08
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther (2009) 1.07
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res (2009) 1.06
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One (2013) 1.04
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res (2010) 1.03
P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate (2004) 1.02
The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. J Pharm Sci (2010) 1.02
Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release (2002) 1.01
Liposomal nanomedicines: an emerging field. Toxicol Pathol (2008) 1.01
Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00
Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther (2007) 1.00
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res (2008) 0.99
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta (2006) 0.99
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther (2006) 0.99
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther (2008) 0.98
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta (2004) 0.95
Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol (2002) 0.93
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces (2012) 0.93
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain. Mol Ther Nucleic Acids (2013) 0.92
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta (2002) 0.92
Effects of block copolymer properties on nanocarrier protection from in vivo clearance. J Control Release (2012) 0.92
Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther (2003) 0.92
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine (2003) 0.91
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm (2006) 0.91
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res (2008) 0.90
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta (2007) 0.90
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer (2012) 0.90
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol (2009) 0.90
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer (2011) 0.90
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther (2002) 0.90
Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J Control Release (2005) 0.90
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res (2004) 0.89
Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol (2007) 0.89
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One (2013) 0.88
Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. Bioconjug Chem (2009) 0.88
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano (2015) 0.88
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release (2010) 0.87
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat (2007) 0.87
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res (2004) 0.87
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release (2004) 0.87
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol (2009) 0.87
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release (2010) 0.87
Disc formation in cholesterol-free liposomes during phase transition. Biochim Biophys Acta (2003) 0.87
Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids. Biochim Biophys Acta (2003) 0.87
Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release (2005) 0.87
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res (2008) 0.86
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther (2002) 0.86
Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol (2002) 0.86
Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv (2010) 0.86
Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm (2007) 0.85
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. PLoS One (2013) 0.85
Advances in Lipid Nanoparticles for siRNA Delivery. Pharmaceutics (2013) 0.85
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta (2002) 0.85
High ceramide content liposomes with in vivo antitumor activity. Anticancer Res (2003) 0.85
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res (2007) 0.85